Ixchel seeks licensees and partners with interest in orphan mitochondrial disease. We are familiar with the clinical trial designs adaptable to orphan mitochondrial disease, thus expediting future development efforts.
© 2017 Ixchel Pharma
Bringing mitochondrial research to life
We are devoted to developing drugs that treat the mechanistic cause of orphan and mitochondrial diseases.
Ixchel Pharma develops small-molecule drugs that ameliorate mitochondrial disease. We have devised a unique approach to identifying therapeutic drugs that hit mitochondrial targets with high specificity. Our approach generates safe therapeutics that target the molecular source of disease to cure the associated symptoms.
Ixchel focuses on developing drugs that cure mitochondrial diseases for which there are currently no FDA-approved treatments. The majority of mitochondrial diseases are considered orphan and affect less than 200,000 people in the US. Ixchel has utilized a repurposing approach to isolate drugs for a number of debilitating orphan mitochondrial diseases including Friedreich’s ataxia (FA), Mitochondrial Myopathy (MM), and Leber’s hereditary optic neuropathy (LHON).